StreetInsider.com News Articles

Form 8-K Sintx Technologies, Inc. For: May 22

Wed, 27 May 2026 15:00:00 -0400

si-local-file:///var/storage/secattach/20260527/26557206.html

Form 8-K Sintx Technologies, Inc. For: May 22

Wed, 27 May 2026 15:00:00 -0400

si-local-file:///var/storage/secattach/20260527/26557206.html

H.C. Wainwright Reiterates Buy Rating on SINTX Tech (SINT)

Wed, 20 May 2026 06:49:42 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $10.00 price target on SINTX Tech (NASDAQ: SINT).

The analyst commented: "SINT reported 1Q26 results which we view as incremental positive, making important steps to transform the company to a successful commercial company. SINT reported revenue of $0.38M was broadly in line with our $0.3M estimate and increased 3% y/y. Excluding the divested TA&T in 2025, remaining revenue increased 46% y/y, product revenue from continuing operations increased 32%, and grant/contract revenue from continuing operations increased 142%. While the absolute revenue base remains small, we view the first quarter as an early

SINTX Technologies to Present at the LD Micro Invitational XVI Conference

Sun, 17 May 2026 15:30:00 -0400

Salt Lake City, Utah--(Newsfile Corp. - May 17, 2026) - SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company"), a medical technology company focused on advanced ceramics and silicon nitride biomaterials, today announced that management will present at the LD Micro Invitational XVI Conference in Los Angeles, California, at the Luxe Sunset Blvd Hotel.

During the presentation, management expects to discuss recent progress in commercialization, product development, and manufacturing initiatives supporting the Company's silicon nitride biomaterials platform, including applications in orthopedics, spine, foot and ankle, and patient-specific implant markets.

"We are pleased to participate in the LD Micro Invitational and look forward

SINTX Technologies to Present at the LD Micro Invitational XVI Conference

Sun, 17 May 2026 15:30:00 -0400

"We are pleased to participate in the LD Micro Invitational and look forward

Form 10-Q Sintx Technologies, Inc. For: Mar 31

Fri, 15 May 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26507534.html

Form 10-Q Sintx Technologies, Inc. For: Mar 31

Fri, 15 May 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26507534.html

Form 4 Sintx Technologies, Inc. For: Apr 13 Filed by: Elmore Robert Ryan

Tue, 14 Apr 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260414/26308953.html

Form 4 Sintx Technologies, Inc. For: Apr 13 Filed by: Elmore Robert Ryan

Tue, 14 Apr 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260414/26308953.html

H.C. Wainwright Starts SINTX Tech (SINT) at Buy

Mon, 13 Apr 2026 06:07:33 -0400

H.C. Wainwright analyst Brandon Folkes initiates coverage on SINTX Tech (NASDAQ: SINT) with a Buy rating (from $10.00).

For an analyst ratings summary and ratings history on SINTX Tech click here. For more ratings news on SINTX Tech click here.

Shares of SINTX Tech closed at $2.68 yesterday.

SINTX Technologies completes first human implant of foot device

Mon, 23 Mar 2026 09:15:20 -0400

SINTX Technologies Inc. (NASDAQ: SINT) completed the first human surgical procedure using its FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System on March 13, 2026, according to a company statement.

The Salt Lake City-based biomaterials company also appointed Ryan Elmore as president effective March 16, 2026. Elmore brings over 15 years of experience in advanced biomaterials and medical device commercialization, including previous leadership roles at Invibio, a division of Victrex plc.

The SINAPTIC system received FDA 510(k) clearance in October 2025 and represents the company's entry into the foot and ankle reconstruction market. SINTX develops silicon nitride technologies for medical applications.

During 2025,

SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

Mon, 23 Mar 2026 09:15:00 -0400

Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026

SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth.